KR101799516B1 - Skin external composition for improving atopic dermatitis and cosmetic composotion including the same - Google Patents
Skin external composition for improving atopic dermatitis and cosmetic composotion including the same Download PDFInfo
- Publication number
- KR101799516B1 KR101799516B1 KR1020170056757A KR20170056757A KR101799516B1 KR 101799516 B1 KR101799516 B1 KR 101799516B1 KR 1020170056757 A KR1020170056757 A KR 1020170056757A KR 20170056757 A KR20170056757 A KR 20170056757A KR 101799516 B1 KR101799516 B1 KR 101799516B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- weight
- parts
- composition
- skin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 발명은 아토피 피부 개선용 피부 외용제 조성물 및 이를 포함하는 화장품에 관한 것이다.The present invention relates to a composition for external application for skin for improving atopic skin and cosmetics containing the same.
피부는 자외선과 같은 외부 자극이나 여러 병원체에 직접 접촉될 기회가 많고, 체내로부터 영향을 강하게 받는다. 또한, 유전, 염증, 양성 및 악성 종양, 호르몬, 외상 및 퇴행변성 등의 병적 변화에도 영향을 받으므로 다양한 원인에 의하여 피부질환이 유발될 수 있다.Skin has many opportunities for external stimuli such as ultraviolet rays, direct contact with various pathogens, and is strongly influenced by the body. It is also affected by pathological changes such as genetic, inflammatory, benign and malignant tumors, hormones, trauma and degenerative degeneration, and skin diseases can be caused by various causes.
염증성 피부질환이란 피부 상피 내에 일련의 염증 반응을 일으키는 다양한 자극 요인들로 인해 가려움, 부종, 홍반, 벗겨짐 등과 같은 일련의 임상적 징후와 증상이 유발되는 질환을 말하며, 아토피성 피부염(atopic dermatitis), 접촉성 피부염(contact dermatitis), 지루성 피부염(seborrhea) 및 여드름 등이 알려져 있다. 현재까지는 상기와 같은 염증성 피부질환을 치료하기 위해서 주로 항히스타민제, 비타민 연고 또는 부신피질호르몬제가 사용되어 왔다. 그러나 이러한 약물은 그 효과가 일시적인 경우가 대부분이고 부작용이 심한 경우도 많다.Inflammatory skin disease refers to a disease in which a variety of stimuli cause a series of inflammatory reactions in the skin epithelium and cause a series of clinical signs and symptoms such as itching, edema, erythema, exfoliation, etc., and include atopic dermatitis, Contact dermatitis, seborrhea and acne are known. Until now, antihistamines, vitamin ointments or corticosteroids have been mainly used to treat inflammatory skin diseases as described above. However, these drugs often have a temporary effect and often have severe side effects.
본 발명은 천연 성분을 이용하여 피부 자극이 적으면서 우수한 효능을 갖는 아토피 피부 개선용 피부 외용제 조성물을 제공하는 것을 목적으로 한다.An object of the present invention is to provide a composition for external skin application for improving atopic skin, which has an excellent efficacy while using fewer skin irritation by using natural ingredients.
본 발명은 상기 조성물을 포함하는 화장품을 제공하는 것을 목적으로 한다.It is an object of the present invention to provide a cosmetic comprising the composition.
1. 고삼 추출물, 백선피 추출물 및 황백 추출물을 포함하는 아토피 피부 개선용 피부 외용제 조성물.1. A composition for external application for skin for improving atopic skin, which comprises a ginseng extract, a white line extract and a yellowish white extract.
2. 위 1에 있어서, 고삼 추출물 100중량부 대비 백선피 추출물 50 내지 200중량부, 황백 추출물 50 내지 200중량부를 포함하는 피부 외용제 조성물.2. The composition for external application for skin according to 1 above, which comprises 50 to 200 parts by weight of a white line extract, and 50 to 200 parts by weight of a yellowish white extract, based on 100 parts by weight of the extract.
3. 위 1에 있어서, 맥문동 추출물 및 황련 추출물을 더 포함하는 피부 외용제 조성물.3. The composition for external application for skin according to 1 above, further comprising mukmun dong extract and Rhodiola extract.
4. 위 3에 있어서, 고삼 추출물 100중량부 대비 맥문동 추출물 50 내지 200중량부, 황련 추출물 50 내지 200중량부를 포함하는 피부 외용제 조성물.4. The composition for external application for skin according to 3 above, which comprises 50 to 200 parts by weight of extracts of mulmunmundum, and 50 to 200 parts by weight of extracts of Mulmunhyang extract, based on 100 parts by weight of the extract.
5. 위 1 내지 4 중 어느 한 항의 조성물로 제조된 화장품.5. A cosmetic product made from the composition of any one of claims 1 to 4.
본 발명의 외용제 조성물은 염증완화 및 진정작용으로 인한 아토피 피부의 개선능이 우수하다. 이에, 화장료, 의약 조성물 등으로 바람직하게 활용될 수 있다.The composition for external application of the present invention is excellent in the ability to ameliorate atopic skin due to inflammation relief and soothing action. Therefore, it can be suitably used as a cosmetic composition, a pharmaceutical composition and the like.
본 발명의 의용제 조성물은 천연물 유래 성분을 포함하여 피부 자극이 적고 알러지 유발 가능성이 희박하다.The composition for cosmetic use of the present invention contains a natural-derived component and has little skin irritation and is unlikely to cause allergy.
이하 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명의 아토피 피부 개선용 피부 외용제 조성물은 고삼 추출물, 백선피 추출물 및 황백 추출물을 포함한다.The composition for external application for skin for improving atopic skin according to the present invention comprises extracts of gossypium, tsutsugamushi, and yellowish white extract.
본 발명자들은 고삼 추출물, 백선피 추출물, 황백 추출물을 함께 사용할 때, 다른 약재 추출물 등의 조합에 비해 현저히 우수한 아토피 개선 효과가 있음을 발견하여 본 발명을 착안하였다.The inventors of the present invention have found that when a combination of a ginseng extract, a white radish extract, and a yellow radish extract is used together with a combination of other medicinal plant extracts and the like, the atopy improving effect is remarkably excellent.
각 추출물은 상기 각 약재를 개별적으로, 또는 혼합하여 용매 추출한 것일 수 있다.Each of the extracts may be obtained by solvent extraction of the respective medicinal materials individually or in combination.
용매는 예를 들면, 물, 탄소수 1 내지 4의 알코올 등일 수 있다. 이들은 단독 또는 2종 이상 혼합하여 사용될 수 있다. The solvent may be, for example, water, an alcohol having 1 to 4 carbon atoms, and the like. These may be used alone or in combination of two or more.
추출 방법은 특별히 한정되지 않으며, 예를 들면 열수 추출, 냉수 추출, 초음파 추출, 환류 추출 등의 방법이 사용될 수 있다.The extraction method is not particularly limited, and for example, methods such as hot water extraction, cold water extraction, ultrasonic extraction, and reflux extraction may be used.
추출 온도는 예를 들면 80 내지 120℃, 구체적으로 90 내지 110℃일 수 있고, 시간은 예를 들면 10분 내지 12시간, 구체적으로 30분 내지 3시간, 보다 구체적으로 1시간 내지 2시간일 수 있으나, 이에 제한되는 것은 아니다.The extraction temperature may be, for example, 80 to 120 ° C, specifically 90 to 110 ° C, and the time may be, for example, 10 minutes to 12 hours, specifically 30 minutes to 3 hours, more specifically 1 hour to 2 hours But is not limited thereto.
필요에 따라 상기 추출물은 여과, 건조 등의 과정을 거친 것일 수 있다.If necessary, the extract may be filtered and dried.
본 발명에 따른 추출물의 함량비는 특별히 한정되지 않으며, 예를 들면 고삼 추출물 100중량부 대비 백선피 추출물 50 내지 200중량부, 황백 추출물 50 내지 200중량부의 비로 포함될 수 있다. 함량비가 상기 범위 내인 경우 아토피 개선 효과가 극대화될 수 있다. 바람직하게는 고삼 추출물 100중량부 대비 백선피 추출물 75 내지 125중량부, 황백 추출물 75 내지 125중량부의 비로 포함될 수 있다.The content ratio of the extract according to the present invention is not particularly limited and may be, for example, a ratio of 50 to 200 parts by weight of the white line extract to 50 to 200 parts by weight of the yellowish white extract, relative to 100 parts by weight of the extract. If the content ratio is within the above range, the atopy improvement effect can be maximized. Preferably 75 to 125 parts by weight of a white line extract, and 75 to 125 parts by weight of a yellowish white extract, based on 100 parts by weight of the extract.
필요에 따라, 본 발명의 아토피 피부 개선용 피부 외용제 조성물은 맥문동 추출물 및 황련 추출물을 더 포함할 수 있다. 그러한 경우에 아토피 개선 효과가 더욱 증대될 수 있다.If desired, the composition for external application for skin for atopic skin improvement of the present invention may further comprise a marshmallow extract and a mulberry extract. In such a case, the atopic improvement effect can be further increased.
맥문동 추출물 및 황련 추출물도 각 약재를 개별적으로, 또는 혼합하여 용매 추출한 것일 수 있다.The extracts of McMundum and Huanglong can also be obtained by solvent extraction of the respective medicines individually or in combination.
추출 방법 및 조건은 상기 범위 내일 수 있으나, 이에 제한되는 것은 아니다.The extraction method and conditions may be within the above range, but are not limited thereto.
맥문동 추출물 및 황련 추출물의 함량은 특별히 한정되지 않으며, 예를 들면 고삼 추출물 100중량부 대비 맥문동 추출물 50 내지 200중량부, 황련 추출물 50 내지 200중량부로 포함될 수 있다. 함량비가 상기 범위 내인 경우 아토피 개선 효과가 극대화될 수 있다. 바람직하게는 고삼 추출물 100중량부 대비 맥문동 추출물 75 내지 125중량부, 황련 추출물 75 내지 125중량부의 비로 포함될 수 있다.There is no particular limitation on the content of the extracts of mungum-dong and rhododendron, for example, 50 to 200 parts by weight of the mung-mun-dong extract and 50 to 200 parts by weight of the mung-mung extract can be contained relative to 100 parts by weight of the extract. If the content ratio is within the above range, the atopy improvement effect can be maximized. Preferably 75 to 125 parts by weight of ginseng extract, and 75 to 125 parts by weight of Ginseng extract, based on 100 parts by weight of the extract.
본 발명의 피부 외용제 조성물은 화장료 조성물 또는 의약 조성물 일 수 있다. 화장료 조성물로 사용시 우수한 아토피 피부 개선능을 가지며, 의약 조성물로 사용시 아토피 피부염의 예방 또는 치료 효과를 나타낼 수 있다.The external preparation for skin of the present invention may be a cosmetic composition or a pharmaceutical composition. It has excellent atopic skin improving ability when it is used as a cosmetic composition, and can exhibit an effect of preventing or treating atopic dermatitis when it is used as a pharmaceutical composition.
본 발명에 따른 화장료 조성물의 외형은 화장품학 또는 피부과학적으로 허용가능한 매질 또는 기제를 함유할 수 있다. 이는 국소적용에 적합한 모든 제형으로, 예를 들면, 용액, 겔, 고체, 반죽 무수 생성물, 수상에 유상을 분산시켜 얻은 에멀젼, 현탁액, 마이크로에멀젼, 마이크로캡슐, 미세과립구 또는, 이온형(리포좀) 및 비이온형의 소낭 분산제의 형태로, 또는 크림, 스킨, 로션, 파우더, 연고, 스프레이 또는 콘실 스틱의 형태로 제공될 수 있다. 이들 조성물은 당해 분야의 통상적인 방법에 따라 제조될 수 있다. 본 발명에 따른 조성물은 또한 포말(foam)의 형태로 또는 압축된 추진제를 더 함유한 에어로졸 조성물의 형태로도 사용될 수 있다.The cosmetic composition composition according to the present invention may contain a cosmetically or dermatologically acceptable medium or base. It may be in any form suitable for topical application, for example, as a solution, a gel, a solid, a paste anhydrous product, an emulsion obtained by dispersing the oil phase in water, a suspension, a microemulsion, a microcapsule, In the form of a non-ionic follicle dispersing agent, or in the form of creams, skins, lotions, powders, ointments, sprays or conical sticks. These compositions may be prepared according to conventional methods in the art. The composition according to the invention may also be used in the form of a foam or in the form of an aerosol composition further containing a compressed propellant.
본 발명의 화장료 조성물은 지방 물질, 유기용매, 용해제, 농축제, 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉쇄제, 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 화장품에 통상적으로 사용되는 임의의 다른 성분과 같은 화장품학 또는 피부과학 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다. 상기 보조제는 화장품학 또는 피부과학 분야에서 일반적으로 사용되는 양으로 도입된다.The cosmetic composition of the present invention can be used as a cosmetic composition in the form of a lipid, an organic solvent, a solubilizer, a thickener, a gelling agent, a softener, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, Cosmetics such as emulsifying agents, fillers, sequestering agents, chelating agents, preservatives, vitamins, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or any other ingredient commonly used in cosmetics Or adjuvants conventionally used in the field of dermatology. Such adjuvants are introduced in amounts commonly used in the cosmetics or dermatological fields.
본 발명의 화장료 조성물은 그 제형에 있어서 특별히 한정되는 바가 없으며, 예를 들면, 유연화장수, 수렴화장수, 영양화장수, 영양크림, 마사지크림, 에센스, 아이크림, 아이에센스, 클렌징크림, 클렌징폼, 클렌징워터, 팩, 파우더, 바디로션, 바디크림, 바디오일 및 바디에센스 등의 화장료로 제형화될 수 있다.The cosmetic composition of the present invention is not particularly limited in its formulation and may be, for example, softening lotion, convergent lotion, nutritional lotion, nutritional cream, massage cream, essence, eye cream, eye essence, cleansing cream, cleansing foam, Water, a pack, a powder, a body lotion, a body cream, a body oil, and a body essence.
본 발명의 피부 외용제 조성물은 의약 조성물일 수 있다. 상기 의약 조성물은 방부제, 안정화제, 수화제 또는 유화 촉진제, 삼투압 조절을 위한 염 및/또는 완충제 등의 약제학적 보조제 및 기타 치료적으로 유용한 물질을 추가로 함유할 수 있다. 상기 의약 조성물은, 로션, 크림, 연고 또는 젤 등으로 제형화될 수 있다.The external preparation for skin of the present invention may be a pharmaceutical composition. The pharmaceutical composition may further contain a preservative, a stabilizer, a wetting agent or an emulsifying accelerator, a pharmaceutical adjuvant such as a salt and / or a buffer for controlling osmotic pressure, and other therapeutically useful substances. The pharmaceutical composition may be formulated into a lotion, cream, ointment or gel.
상기 의약 조성물은, 경피 투여되는 것이 바람직하다.The pharmaceutical composition is preferably transdermally administered.
상기 의약 조성물의 유효성분인 추출물의 투여량은 치료 받을 대상의 연령, 성별, 체중과, 치료할 특정 질환 또는 병리 상태, 질환 또는 병리 상태의 심각도, 투여경로 및 처방자의 판단에 따라 달라질 것이다. 이러한 인자에 기초한 투여량 결정은 당업자의 수준 내에 있다. 일반적으로 투여량은 0.0001 mg/kg/일 내지 대략 2000 g/kg/일 범위이다.The dosage of the extract as an active ingredient of the above pharmaceutical composition will depend on the age, sex, and weight of the subject to be treated, the specific disease or pathological condition to be treated, the severity of the disease or pathological condition, the administration route and the judgment of the prescriber. Dosage determinations based on these factors are within the level of those skilled in the art. Generally, the dosage ranges from 0.0001 mg / kg / day to about 2000 g / kg / day.
이하, 본 발명을 구체적으로 설명하기 위해 실시예를 들어 상세하게 설명하기로 한다. BEST MODE FOR CARRYING OUT THE INVENTION Hereinafter, the present invention will be described in detail with reference to examples.
실시예Example
1. 추출물의 제조1. Preparation of extract
각 추출물은 각 약재를 10배 중량의 물에 넣고 95℃, 1시간 30분 추출하고, 여지로 감압 여과하였다. 여과된 추출물을 4℃에서 24시간 냉장보관한 후 이를 다시 여과하여 추출물을 얻고 이를 4℃에서 냉장 보관하였다.Each of the extracts was subjected to extraction at 95 ° C for 1 hour and 30 minutes by adding 10 times the weight of each of the medicinal materials, followed by filtration under reduced pressure. The filtered extract was refrigerated at 4 ° C for 24 hours, and then filtered again to obtain an extract, which was stored at 4 ° C in a refrigerator.
2. 조성물의 제조2. Preparation of the composition
하기 표 1에 기재된 성분들을 해당 함량(중량부)으로 혼합하여 조성물을 제조하였다.The components shown in Table 1 were mixed in the respective amounts (parts by weight) to prepare a composition.
실험예Experimental Example
1. 아토피 유발 마우스 모델1. Atopy-induced mouse model
무처리군(normal), DNCB 군, tacrolimus 군, 실시예 처리군 및 비교예 처리군의 총 5그룹으로 나누어, 그룹별로 각각 5마리(각 실시예, 비교예별로 5마리)의 NC/Nga 마우스를 이용해 평가하였다. NC/Nga 마우스의 등 및 목 부위에 제모 크림을 0.1g 도포하고 상처가 나지 않도록 부드러운 티슈를 사용하여 털을 제거 하였다. 미세상처가 아물도록 5일 동안 방치한 후, 주 3회씩 2주간 1% DNCB 200㎕ (아세톤: 올리브오일= 3:1)를 등과 귀에 도포하여 아토피를 유도하였다. 아토피가 유도된 후에는 주 2회씩 4주간 실시예, 비교예 추출물을 환부에 100mg/kg으로 도포하였다. 효능을 비교하기 위하여 아토피 치료제로 사용중인 tacrolimus를 사용하였다. tacrolimus는 아토피 환부에 100mg/kg으로 주 2회씩 4주간 도포하였다.Nca mice were divided into five groups (five in each of the Examples and Comparative Examples), each of which was divided into five groups, namely, a non-treated group (normal), a DNCB group, a tacrolimus group, . 0.1 g of hair removal cream was applied to the back and neck of the NC / Nga mouse and the hair was removed using a soft tissue to prevent scratching. After leaving for 5 days so as to keep the fine scratches, atopic dermatitis was induced by applying 200 μl of 1% DNCB (acetone: olive oil = 3: 1) three times a week for 2 weeks. After induction of atopy, the extracts of Example and Comparative Example were applied to the affected area at 100 mg / kg twice a week for 4 weeks. To compare efficacy, tacrolimus was used as a treatment for atopy. Tacrolimus was applied to the atopic lesion at 100 mg / kg twice a week for 4 weeks.
2. 아토피 유발 마우스 모델에서의 아토피 2. Atopy in atopy-induced mouse models 개선능Improvement ability
(( 1)혈청1) Serum IgEIgE 저해 효과 Inhibitory effect
시험물질 처리 종료 후, DNCB로 아토피가 유도된 대조군 마우스와 실시예 및 비교예 처리군 마우스 및 tacrolimus를 처리한 마우스를 희생시키고 심장에서 혈액을 채취하였고, 이로부터 혈청을 분리하여 IgE 를 측정하였다. 구체적으로 IgE ELISA Kit(BD Biosciences, San Diego, CA)를 사용하여, 항체를 완충용액에 희석하여 96-well plate에 부착하여 4℃에서 밤새 정치하고 매뉴얼에 따라 실험을 진행하였다. IgE의 단백질량은 microplate reader로 450nm에서 흡광도를 측정하였다. After completion of treatment with the test substance, control mice in which atopy was induced by DNCB, mice treated with the group of the Example and Comparative Example and mice treated with tacrolimus were sacrificed, blood was collected from the heart, and serum was separated therefrom to measure IgE. Specifically, the antibody was diluted in a buffer solution using an IgE ELISA Kit (BD Biosciences, San Diego, Calif.), Adhered to a 96-well plate, allowed to stand overnight at 4 ° C, and the experiment was conducted according to the manual. The amount of IgE protein was measured with a microplate reader at 450 nm.
심장에서 혈액을 채취하여 분리시킨 혈청으로부터 알러지 질환을 매개하는 IgE의 양을 IgE ELISA Kit를 사용하여 측정한 결과를 표 2에 나타내었다.The amount of IgE mediating allergic diseases from the serum collected from the blood from the heart was measured using an IgE ELISA kit, and the results are shown in Table 2.
상기 표 2를 참조하면 DNCB에 의해 아토피 유도된 NC/Nga 마우스에 비해 tacrolimus와 실시예 처리군 NC/Nga 마우스에서는 IgE가 감소한 것을 확인할 수 있었다.Referring to Table 2 above, it was confirmed that tacrolimus was reduced compared with NC / Nga mice induced by DNCB and IgE was decreased in NC / Nga mice treated with the group of the examples.
(2) 피부의 (2) the skin 함습도Humidity 측정 Measure
상기 각 군의 마우스의 등 피부 함습도(%)를 3주간 매주 1회 corneometer CM820(Courage & Khazaka, Cologne, Germany)와 tewameter TM210(Courage & Khazaka, Cologne, Germany)로 측정하였다.The percent humidities (%) of the mice in each of the above groups were measured once weekly with a corneometer CM820 (Courage & Khazaka, Cologne, Germany) and tewameter TM210 (Courage & Khazaka, Cologne, Germany) for 3 weeks.
상기 표 3을 참조하면, 실시예 처리군 NC/Nga 마우스에서는 피부 함습도가 높은 것을 확인할 수 있다.Referring to Table 3 above, it can be seen that the skin humidity was high in the NC / Nga mice treated in the Examples.
Claims (5)
Wherein the medicinal composition comprises at least one extract selected from the group consisting of ginseng extract, white radish extract and yellowish white extract, wherein at least 50 to 200 parts by weight of the white radish extract and 50 to 200 parts by weight of the yellowish white extract, A cosmetic composition for improvement.
[3] The pharmaceutical composition according to claim 1, wherein the medicinal plant extract comprises 50 to 200 parts by weight of the extract of Bombyx mori extract, 50 to 200 parts by weight of a yellowish white extract, 50 to 200 parts by weight of a yellowish white extract, 50 to 200 parts by weight of the extract of marshmallow extract, 50 to 200 parts by weight of the extract of the mulberry extract.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170056757A KR101799516B1 (en) | 2017-05-04 | 2017-05-04 | Skin external composition for improving atopic dermatitis and cosmetic composotion including the same |
| PCT/KR2018/005104 WO2018203668A1 (en) | 2017-05-04 | 2018-05-02 | External-use skin preparation composition for alleviating atopic skin, and cosmetic containing same |
| TW107115075A TW201842928A (en) | 2017-05-04 | 2018-05-03 | Skin external composition for improving atopic dermatitis and cosmetic composition including the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170056757A KR101799516B1 (en) | 2017-05-04 | 2017-05-04 | Skin external composition for improving atopic dermatitis and cosmetic composotion including the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR101799516B1 true KR101799516B1 (en) | 2017-11-20 |
Family
ID=60809241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170056757A KR101799516B1 (en) | 2017-05-04 | 2017-05-04 | Skin external composition for improving atopic dermatitis and cosmetic composotion including the same |
Country Status (3)
| Country | Link |
|---|---|
| KR (1) | KR101799516B1 (en) |
| TW (1) | TW201842928A (en) |
| WO (1) | WO2018203668A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018203668A1 (en) * | 2017-05-04 | 2018-11-08 | 이종열 | External-use skin preparation composition for alleviating atopic skin, and cosmetic containing same |
| WO2021150088A1 (en) * | 2020-01-23 | 2021-07-29 | 주식회사 엘케이 | Pharmaceutical composition, pharmaceutical composition for animal, and food composition, each comprising natural substance extract, and preparation method therefor |
| KR20210095482A (en) * | 2020-01-23 | 2021-08-02 | 주식회사 엘케이 | Cosmetic composition for atopic dermatitis |
| KR102537948B1 (en) * | 2022-06-08 | 2023-05-30 | 윤석호 | Composition for improvement or treatment of atopic dermatitis containing natural complex components and preparing method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101676601B1 (en) | 2016-04-22 | 2016-11-15 | 양형열 | External preparation for skin comprising herbal extracts as an active ingredient and manufacturing method thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100742378B1 (en) * | 2005-05-17 | 2007-07-24 | 김정진 | Composition containing herb medicine for treating atopic dermatitis |
| KR101051362B1 (en) * | 2007-08-31 | 2011-07-22 | (주)콤비메드 | Atopic Dermatitis Treatment and / or Prevention Composition Comprising Herbal Fermentation Products |
| KR20100044502A (en) * | 2008-10-22 | 2010-04-30 | 이정미 | Cleaning solution for body by using natural material |
| KR101300701B1 (en) * | 2010-11-17 | 2013-08-26 | 주식회사 에이치플랜 | The cosmetics to have an atopic dermatitis improvement efficacy making method besides |
| KR101367423B1 (en) * | 2011-12-29 | 2014-02-28 | 원광대학교산학협력단 | Pharmaceutical composition and cosmetic compostion for improving skin condition and preparation method thereof |
| KR101799516B1 (en) * | 2017-05-04 | 2017-11-20 | 이종열 | Skin external composition for improving atopic dermatitis and cosmetic composotion including the same |
-
2017
- 2017-05-04 KR KR1020170056757A patent/KR101799516B1/en active IP Right Grant
-
2018
- 2018-05-02 WO PCT/KR2018/005104 patent/WO2018203668A1/en active Application Filing
- 2018-05-03 TW TW107115075A patent/TW201842928A/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101676601B1 (en) | 2016-04-22 | 2016-11-15 | 양형열 | External preparation for skin comprising herbal extracts as an active ingredient and manufacturing method thereof |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018203668A1 (en) * | 2017-05-04 | 2018-11-08 | 이종열 | External-use skin preparation composition for alleviating atopic skin, and cosmetic containing same |
| WO2021150088A1 (en) * | 2020-01-23 | 2021-07-29 | 주식회사 엘케이 | Pharmaceutical composition, pharmaceutical composition for animal, and food composition, each comprising natural substance extract, and preparation method therefor |
| KR20210095482A (en) * | 2020-01-23 | 2021-08-02 | 주식회사 엘케이 | Cosmetic composition for atopic dermatitis |
| KR20210095594A (en) * | 2020-01-23 | 2021-08-02 | 주식회사 엘케이 | A food composition comprising natural material extracts and a preparing method thereof |
| KR20210095593A (en) * | 2020-01-23 | 2021-08-02 | 주식회사 엘케이 | A pharmaceutical composition for animal comprising natural material extracts and a preparing method thereof |
| KR20210095592A (en) * | 2020-01-23 | 2021-08-02 | 주식회사 엘케이 | A pharmaceutical composition comprising natural material extracts and a preparing method thereof |
| KR102362903B1 (en) * | 2020-01-23 | 2022-02-15 | 주식회사 엘케이 | A food composition comprising natural material extracts and a preparing method thereof |
| KR102362901B1 (en) * | 2020-01-23 | 2022-02-15 | 주식회사 엘케이 | A pharmaceutical composition comprising natural material extracts and a preparing method thereof |
| KR102362902B1 (en) * | 2020-01-23 | 2022-02-15 | 주식회사 엘케이 | A pharmaceutical composition for animal comprising natural material extracts and a preparing method thereof |
| KR102447044B1 (en) * | 2020-01-23 | 2022-09-26 | 주식회사 엘케이 | Cosmetic composition for anti-oxidation or whitening |
| US20220354917A1 (en) * | 2020-01-23 | 2022-11-10 | Lk. Inc. | Pharmaceutical composition, pharmaceutical composition for animal, and food composition, each comprising natural substance extract, and preparation method therefor |
| JP2023511684A (en) * | 2020-01-23 | 2023-03-22 | エルケイ・インコーポレイテッド | Natural material extract-containing pharmaceutical composition, veterinary pharmaceutical composition, food composition and method for producing the same |
| KR102537948B1 (en) * | 2022-06-08 | 2023-05-30 | 윤석호 | Composition for improvement or treatment of atopic dermatitis containing natural complex components and preparing method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018203668A1 (en) | 2018-11-08 |
| TW201842928A (en) | 2018-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101799516B1 (en) | Skin external composition for improving atopic dermatitis and cosmetic composotion including the same | |
| KR101017709B1 (en) | Cosmetic composition comprising the herbal mixed extract comprising panax ginseng c.a meyer showing hair-growth stimulating activity and preventing activity from hair loss | |
| JP2010518180A (en) | Novel cosmetic and / or pharmaceutical compositions and their uses | |
| KR102300581B1 (en) | Compositions for improving skin conditions comprising plant extracts or fractions thereof | |
| KR102214985B1 (en) | Compositions for improving skin conditions comprising plant extracts or fractions thereof | |
| KR101848474B1 (en) | Nature-derived cosmetic composition for relieving itching of atopic skin and the method for preparing the same | |
| KR102598042B1 (en) | Composition having centipeda minima extracts for anti-inflammatory, preventing and curing autoimmune disease and manufacturing method thereof | |
| KR20090079468A (en) | Compositions of cosmetics for irritation- soothing or anti-itching effect containing spirulina extract | |
| US20010014343A1 (en) | Skin care composition | |
| KR101083299B1 (en) | Skin external application composition for preventing or treating inflammatory skin disease | |
| KR20070000675A (en) | Composition containing mung bean extract, bletillae tuber extract and black cohosh extract and use thereof | |
| KR102027647B1 (en) | Low irritating cosmetic composition for skin whitening comprising albutin | |
| KR101134790B1 (en) | Composition for improving acne skin containing Hinokitiol and Ampelopsis radix extract | |
| KR102221627B1 (en) | Composition comprising Rhus Semialata extract as active ingredient | |
| KR20220104655A (en) | Composition for treating acne containing nanoized bee pollen extract as an active ingredient | |
| KR101648466B1 (en) | Cosmetic composition for improving skin | |
| KR102337357B1 (en) | Cosmetic composition for skin regenerating containing Panax Ginseng root extract, Madecassoside, Oenothera Biennis seed oil and Carthamus Tinctorius seed oil | |
| KR20060099225A (en) | Composition containing hovenia dulcis fruit extract having anti-inflammatory effect and use thereof | |
| KR101605517B1 (en) | Manufacturing method for cosmetic composition for improving acne and cosmetic compostion thereof | |
| KR20210132346A (en) | Cosmetic composition for salleviating skin itching and preventing or improving skin damage due to burns | |
| KR100954984B1 (en) | Anti-inflammatory cosmetic compositions containing of herb medicines | |
| KR20150050980A (en) | Cosmetic composition and external composition comprising Withania somnifera for anti-inflammatory | |
| KR20130016929A (en) | The cosmetic composition for pore-minimizing and inhibition of sebum secretion containing the extract of leaves of mentha arvensis var. piperascens, wheat bud, and platycodon grandiflorum | |
| KR102621129B1 (en) | Natural cosmetic composition using grains and herbal medicines | |
| KR101979658B1 (en) | Manufacturing method of composition for hair-loss prevention and hair growth using shungite |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AMND | Amendment | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant |